Cetera Investment Advisers Purchases 910,062 Shares of ImmunityBio, Inc. $IBRX

Cetera Investment Advisers grew its holdings in ImmunityBio, Inc. (NASDAQ:IBRX) by 2,483.3% during the 1st quarter, HoldingsChannel reports. The firm owned 946,709 shares of the company’s stock after acquiring an additional 910,062 shares during the quarter. Cetera Investment Advisers’ holdings in ImmunityBio were worth $7,261,000 as of its most recent filing with the SEC.

A number of other institutional investors have also made changes to their positions in the business. AQR Capital Management LLC boosted its stake in ImmunityBio by 193.4% during the 1st quarter. AQR Capital Management LLC now owns 44,448 shares of the company’s stock valued at $134,000 after purchasing an additional 29,297 shares during the period. Creative Planning lifted its holdings in shares of ImmunityBio by 9.2% during the second quarter. Creative Planning now owns 62,028 shares of the company’s stock worth $164,000 after buying an additional 5,231 shares during the last quarter. JPMorgan Chase & Co. lifted its holdings in shares of ImmunityBio by 5.2% during the second quarter. JPMorgan Chase & Co. now owns 1,071,736 shares of the company’s stock worth $2,829,000 after buying an additional 52,782 shares during the last quarter. Legal & General Group Plc boosted its position in shares of ImmunityBio by 11.8% in the second quarter. Legal & General Group Plc now owns 205,478 shares of the company’s stock valued at $542,000 after acquiring an additional 21,715 shares during the period. Finally, Franklin Resources Inc. bought a new stake in shares of ImmunityBio in the second quarter valued at approximately $230,000. 8.58% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

IBRX has been the topic of a number of research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of ImmunityBio in a research report on Friday, July 10th. D. Boral Capital reissued a “buy” rating and issued a $23.00 price target on shares of ImmunityBio in a report on Tuesday, May 5th. BTIG Research restated a “buy” rating and issued a $12.00 price target on shares of ImmunityBio in a research report on Thursday, May 21st. Finally, HC Wainwright restated a “buy” rating and set a $15.00 price objective on shares of ImmunityBio in a report on Tuesday, June 2nd. Six equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $14.20.

ImmunityBio Trading Down 3.8%

Shares of NASDAQ:IBRX opened at $7.17 on Friday. ImmunityBio, Inc. has a 1-year low of $1.95 and a 1-year high of $12.43. The firm has a market capitalization of $7.51 billion, a PE ratio of -8.44 and a beta of 0.01. The business’s 50 day moving average is $7.70 and its 200-day moving average is $7.52.

ImmunityBio (NASDAQ:IBRX) last released its quarterly earnings data on Thursday, May 7th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.54). The firm had revenue of $44.21 million during the quarter, compared to analyst estimates of $43.07 million. On average, sell-side analysts predict that ImmunityBio, Inc. will post -0.31 EPS for the current year.

Insiders Place Their Bets

In other news, Director Christobel Selecky sold 159,478 shares of the firm’s stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $9.02, for a total transaction of $1,438,491.56. Following the completion of the transaction, the director directly owned 35,064 shares of the company’s stock, valued at approximately $316,277.28. This trade represents a 81.98% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Cheryl Cohen sold 131,210 shares of the firm’s stock in a transaction dated Thursday, July 2nd. The stock was sold at an average price of $9.50, for a total transaction of $1,246,495.00. Following the transaction, the director directly owned 125,386 shares of the company’s stock, valued at $1,191,167. The trade was a 51.13% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 435,443 shares of company stock worth $3,918,819 over the last 90 days. Corporate insiders own 66.10% of the company’s stock.

ImmunityBio Company Profile

ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.

Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.